The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Repositioning Drugs for PD, 2011Droxidopa Treatment for Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Memory, concentration, and other cognitive operations are sometimes impaired in Parkinson's disease (PD), but available treatment options are very limited. This project will test... -
Rapid Response Innovation Awards, 2011Pathogenic Significance of the Hyperpolarization-activated Current (Ih) in the Degeneration of Dopaminergic Neurons
Objective/Rationale:
The neurotoxin MPTP is believed to kill nigral dopaminergic neurons by inhibiting mitochondrial metabolism, thus producing Parkinson’s signs in pre-clinical models. Recent studies... -
MJFF Research Grant, 2011GeneGo LRRK2 Pathway Map - Laura Brovold (GeneGo/Thomson Reuters)
Objective/Rationale:
Human diseases are inherently complex and involve a multitude of interconnected proteins, which function in groups defined as pathways and complexes. In order to understand... -
Dyskinesia, 2011Role of Gad1 in l-DOPA-induced dyskinesias
Objective/Rationale:
Levodopa remains the most efficient agent used for the Symptoms & Side Effects treatment of Parkinson’s disease. Unfortunately, levodopa administration for several years also... -
MJFF Research Grant, 2011Estimating Neuroprotective Effects of Nigral AAV-NRTN Using Selective Reaction Monitoring to Quantitatively Measure p-erk1/2 Signaling Strength in Nigral DA Neurons
Objective/Rationale:
Pre-clinical studies indicate that neurotrophic factor gene therapy has the potential to attenuate, delay and perhaps prevent the progressive loss of nigral DA neurons in aging... -
Dyskinesia, 2011Development of a Treatment for Dyskinesia Targeting Opioid Receptors
Objective/Rationale:
Levodopa-induced dyskinesias (LID) affect the majority of patients with advanced Parkinson’s disease, compounding their disability. Therefore, drugs that prevent or limit LID are...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.